Fennec Pharmaceuticals Inc has seen a slight decline in its stock price this week despite reporting record sales for its fiscal year 2025.
Fennec Pharmaceuticals Inc (FRX.TO) experienced a price drop of 3.70% on Thursday, bringing its 1-day performance down to C$16.38. Over the past week, the stock has seen a minor decline of 0.79%, although it has shown significant growth of 15.19% over the past month and a remarkable 57.35% year-to-date. This week's movements come on the heels of the company's announcement of record net product sales for FY2025.
Advertisement
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$596.49M
52W high
$17.64
52W low
$7.59
1W change
-0.79%
Beta
1.07
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 471.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+471.2% Upside
Current Price
C$16.38
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
64.4%
Annualized
90-Day Vol
80.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$19.58
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$17.38 | C$13.92 – C$21.71 |
| 60 trading days | C$18.45 | C$13.47 – C$25.27 |
| 90 trading days | C$19.58 | C$13.32 – C$28.78 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should note the recent sales growth and the stock's performance trends, while also considering the lack of major news that may contribute to price fluctuations.
Fennec Pharmaceuticals Reports Record FY2025 Net Product Sales of $44.6M.
The company's fourth-quarter sales reached $13.8 million, a 75% increase compared to the same period last year, showcasing strong growth potential.
Bull case
The company reported a 50% year-over-year increase in net product sales for FY2025, showing strong demand for its offerings, particularly PEDMARK®.
Bear case
The recent price decline and low trading volume compared to the 20-day average may raise concerns among investors.
Price Action Overview
Advertisement
Fennec Pharmaceuticals Inc's stock closed at C$16.38 on Thursday, down 3.70% for the day. The stock has experienced a slight decline of 0.79% over the past week, while its month-to-date performance is up 15.19%. Year-to-date, the stock has surged by 57.35%, reflecting strong investor interest.
Recent Company News
Fennec Pharmaceuticals recently announced record FY2025 net product sales of $44.6 million, marking a 50% increase year-over-year. The fourth quarter alone contributed $13.8 million, a 75% increase compared to Q4 2024. This strong performance highlights the growing demand for its product PEDMARK®, which is aimed at reducing the risk of hearing loss in pediatric patients undergoing chemotherapy.
Technical Picture
From a technical standpoint, Fennec Pharmaceuticals' stock is currently trading well above its 50-day moving average of C$14.52, representing a 12.8% increase. The 200-day moving average stands at C$11.63, indicating a 40.8% premium to the current price. The stock has a 52-week range of C$7.59 to C$17.64, and its beta is 1.07, suggesting it is slightly more volatile than the market. However, the recent trading volume of 104 shares is significantly lower than the 20-day average of 843 shares, indicating reduced trading activity.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
